Type 2 Diabetes
Chronic high blood sugar from insulin resistance and pancreatic strain — tightly interwoven with weight and GLP-1 therapy.
Type 2 diabetes develops when insulin resistance outruns the pancreas's ability to compensate: glucose stays elevated (HbA1c 6.5%+), quietly damaging vessels, nerves, kidneys, and eyes. Excess weight — particularly visceral fat — is its dominant modifiable driver, and the two conditions amplify each other.
The GLP-1 era blurred the old treatment boundary: drugs built for diabetes (Ozempic, Mounjaro) turned out to treat weight; drugs built for weight improve glucose enough that diabetes remission became a mainstream clinical goal. Patients with both conditions should note one honest asymmetry from trials — weight-loss averages run somewhat smaller in diabetic populations — and one coordination rule: other diabetes medications (insulin, sulfonylureas) usually need adjusting as GLP-1 therapy takes hold.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Type 2 Diabetes? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment